<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220802</date><key>pmc.key</key><document><id>9285112</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.3205/dgkh000416</infon><infon key="article-id_other">urn:nbn:de:0183-dgkh0004165</infon><infon key="article-id_pmc">9285112</infon><infon key="article-id_pmid">35909651</infon><infon key="article-id_publisher-id">dgkh000416 Doc13</infon><infon key="elocation-id">Doc13</infon><infon key="kwd">guideline virucidal gargling virucidal nasal spray SARS-CoV-2 COVID-19</infon><infon key="license">This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.</infon><infon key="name_0">surname:Kramer;given-names:Axel</infon><infon key="name_1">surname:Eggers;given-names:Maren</infon><infon key="name_2">surname:Exner;given-names:Martin</infon><infon key="name_3">surname:Hübner;given-names:Nils-Olaf</infon><infon key="name_4">surname:Simon;given-names:Arne</infon><infon key="name_5">surname:Steinmann;given-names:Eike</infon><infon key="name_6">surname:Walger;given-names:Peter</infon><infon key="name_7">surname:Zwicker;given-names:Paula</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">17</infon><infon key="year">2022</infon><offset>0</offset><text>Recommendation of the German Society of Hospital Hygiene (DGKH): Prevention of COVID-19 by virucidal gargling and virucidal nasal spray – updated version April 2022</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>167</offset><text>The German Society of Hospital Hygiene develops guidelines, recommendations and standard operation procedures on a voluntary basis, published on the DGKH-website (https://www.krankenhaushygiene.de/).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>367</offset><text>The original German version of this recommendation was published in April 2022 and has now been made available to the international professional public in English. Evaluating the current data on the efficacy of virucidal gargle/mouthwash solutions and nasal sprays against SARS-CoV-2 in vitro and in clinical trials, conducted with preventive or therapeutic objectives, recommendations are given for the prevention of COVID-19. The following areas are considered: </text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>832</offset><text>Protection of the community when regional clusters or high incidences of infection become known</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>928</offset><text>Protection of the community at low risk of infection</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>981</offset><text>Pre-exposure prophylaxis for the protection of healthcare workers</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1047</offset><text>Post-exposure prophylaxis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1073</offset><text>1. Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1089</offset><text>To prevent COVID-19, all available hygienic measures must be implemented to protect the community and, in particular, highly exposed individuals such as medical personnel. Personal behaviors, including adherence to distance rules and social contact restrictions, wearing of nose-mouth mask, vaccination, virucidal prevention in the nasopharynx, healthy diet, and physical activity, are primarily the responsibility of the individual, but are significantly influenced by intergenerational coexistence, living space, educational level, socioeconomic status, and, in the case of vaccination, additional misleading misinformation based on conspiracy theories,,,. Particularly in the generation over 60 years old, government recommendations for infection-preventive behavior correlate significantly with their implementation in the everyday life. Therefore, the prevention potential of virucidal antisepsis in the nasopharynx, which has received too little attention so far, should be given the importance it warrants in public relations and recommendations to popularize it as an easy-to-implement preventive measure. This can be used to supplement infection prevention for occupationally exposed personnel, but also for contact persons living in the same household with SARS CoV-2 infected persons or persons suffering from COVID-19. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2421</offset><text>The following statements reflect the current state of knowledge regarding the efficacy of antiseptics in the prevention of SARS-CoV-2 infections.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2567</offset><text>The entry site for SARS-CoV-2 is the nasopharyngeal cavity. In the delta variant the viral load in nasopharyngeal swabs is higher than in saliva [6], in the omicron variant vice versa [7], so that both areas must be included in virucidal antisepsis. Presumably, infection can also occur via the eye, provided droplets reach the eye directly,. Because a large proportion of infected individuals release the virus before the onset of initial symptoms, protective measures that reduce the viral load at the ports of entry, i.e., the nasopharynx, are useful because the likelihood of contracting the infection increases with the extent of exposure. Because the initial viral load also influences the severity of disease after infection, virucidal antisepsis at the ports of entry may even mitigate manifesting infection during the course of disease,,,. </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3417</offset><text>Gargling was long used to reduce upper respiratory tract infections and to treat bacterial/viral infections (e.g., strep throat, common cold), but has now fallen out of fashion. Hand washing with soap and water and gargling with saline solution were recommended to the population in Germany by the State Health Council as a preventive measure as early as during the Spanish flu in 1918. In former East Germany, school children were advised to gargle with diluted potassium permanganate solution when entering summer holiday camp. Furthermore, the beneficial soothing effect of salty air on the respiratory tract has been known for centuries. It stimulates the natural self-cleaning of the respiratory tract and prevents the mucous membranes from desiccating. In addition, moistening the mucous membranes of the mouth and nose prevents the adhesion of viruses and is therefore preventively effective even without the use of solutions/sprays with their own antiviral efficacy,. In contrast to Europe, daily gargling with saline has a long tradition in Japan and in Korea for the prevention of respiratory infections. Gargling was increasingly promoted by the Japanese Ministry of Health, Labour and Welfare during the 2009 H1N1 swine flu pandemic and has been explicitly recommended as a daily routine for the general public since the COVID-19 pandemic began.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4775</offset><text>To exploit antiseptic use in the nasopharynx as an easily realizable measure and prophylactic instrument for the prevention and control of COVID-19 in Germany, knowledge on the virucidal efficacy and preventive use options of nasal sprays and gargle solutions is summarized below. A decisive advantage of antiseptic measures is that if a gargle solution or nasal spray is proven to be effective against SARS-CoV-2, the effect is directed against all variants of the virus and at the same time other respiratory enveloped viruses, such as influenza viruses.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>5332</offset><text>2. State of knowledge on the virucidal efficacy of mouthrinse/gargle solutions and nasal sprays</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5428</offset><text>To limit the bibliography, sources cited in the review by Kramer and Eggers are not explicitly listed, only indirectly with reference to this review.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>5578</offset><text>2.1 In vitro efficacy </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5601</offset><text>Efficacy against SARS-CoV-2 has been proven for the following agents or formulations,,,,,,,,,,,,,,,,,: </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5705</offset><text>PVP-iodine ≥0.23% with an exposure time of 15–60 s, applicable in the oral cavity, nasal cavity, and eye.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5815</offset><text>Mouth- or gargle rinses based on </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5849</offset><text>essential oils, </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5866</offset><text>dequalinium chloride, </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5889</offset><text>without or with content of ethanol/benzalkonium chloride (Dequonal®), </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5961</offset><text>phenoxyethanol + octenidine (Octenisept®), </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6006</offset><text> ethanol + ethyl laurylarginate,  </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6041</offset><text> delmopinol hydrochloride,  </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6070</offset><text> di-potassium oxalate,  </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6095</offset><text>cetylpyridinium chloride (CPC), and </text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6132</offset><text>PHTALOX®, a phthalocyanine derivative.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6172</offset><text>PVP-iodine from 0.5% induces complete virus inactivation within 15 s, which is achieved by 70% ethanol after 30 s.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6287</offset><text>For mouthrinses based on essential oils, complete inactivation of SARS-CoV-2 was verified both with alcohol content (Listerine® Cool Mint) and without alcohol content (Listerine® Cool Mint mild taste). In contrast, mouthrinses based on hydrogen peroxide (HPO), polihexanide, chlorhexidine digluconate (CHG), or octenidine (the latter without combination with phenoxyethanol) were not sufficiently effective,,. Consistently, CHG was also ineffective in the oral cavity. Studies in which CHG had been found to be effective were apparently based on incomplete neutralization of CHG adsorbed to virus and only simulated efficacy. Results differ for stabilized hypochlorite.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6959</offset><text>Green tea, pomegranate juice, and aronia juice are effective against various pathogens of respiratory infections; however, the efficacy is lower than that of the mouthrinses mentioned above. Aronia juice has now also been shown to be effective against SARS-CoV-2. Green tea reduces the titer of SARS-CoV-2 by 80% after 1 min. For sage extract, efficacy against influenza and human corona viruses has been demonstrated, and sage extract was therapeutically as effective as the antiviral aciclovir against herpes labialis; thus, it is highly likely that it is also effective against SARS-CoV-2.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7552</offset><text>Nasal sprays based on saline (0.9%), xylometazoline hydrochloride (0.1%), and the combinations hydroxypropylmethylcellulose/succinic acid/disodium succinate or Galphimia glauca/ Luffa operculata/ Sabadilla were ineffective. The combination of sodium hypochlorite (&lt;0.08%) with lithium magnesium sodium silicate achieved a reduction factor of 2.2, which, however, is not considered sufficient for virucidal activity. Since the product forms a gel matrix that may interfere with the virus, an effect may be achieved in vivo if need be. However, the tolerability of sodium hypochlorite for long-term use requires clarification.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>8177</offset><text>2.2 Preventive efficacy in in vivo and in-use studies</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>8231</offset><text>Gargling</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8240</offset><text>Gargling with hypertonic saline (2%–3%) 3 times/d significantly shortened the duration of illness from viral influenza, with the reduction in viral shedding reducing the incidence of illness by 35%, even among people living in the same household. Since saline is not virucidal in vitro, hypochlorite is probably formed intracellularly due to the increased chlorite availability; it is also possible that viral adherence is reduced.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8674</offset><text>Green tea also reduced the manifestation of viral influenza by 30% compared with water or no gargling (5 studies).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8789</offset><text>However, a higher protective effect is achieved by using virucidal antiseptics. For example, rinsing the oral cavity with 1% PVP-iodine solution for 1 min significantly reduced the amount of SARS-CoV-2 in saliva with high viral load for the duration of 3 h. In another study, both PVP-iodine and CPC significantly decreased the recovery of viral load compared with rinsing with water for the duration of the 6 h-study.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9208</offset><text>In vivo, the lack of efficacy of 1% HPO and the low efficacy of CHG, were confirmed. In a RCT, after a single mouth rinsing, virus levels were insufficiently reduced, by only 61–89% after 15 min, regardless of whether 0.12% CHG, 1% HPO, saline, or 0.5% PVP-iodine was used, i.e., a single rinse is not sufficient for a sustained effect. Similarly, a single rinse with sorbitol and xylitol (Linolasept® mouthwash) reduced the viral load by 90%, that means 1 lg.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>9672</offset><text>Nasal spray</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9684</offset><text>Although carragelose does not inactivate SARS-CoV-2 in vitro, it inhibits viral replication in vitro,. In 3 studies (n&gt;600), application as nasal spray significantly reduced the duration of illness and the number of patients with symptoms in respiratory infections caused by human rhino, corona, and influenza A viruses, respectively. The viral load was significantly lower in the verum group than in the placebo group. The hypothesized mode of action is that the high molecular weight polymer of the sugar-like molecule galactose forms a mucoadhesive layer on the nasal mucosa that interacts with the virus.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>10293</offset><text>2.3 Therapeutic efficacy in in-use studies</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>10336</offset><text>Gargling</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10345</offset><text>When the combination of ethanol with essential oils was used for mouthrinsing in cases of H. simplex, HSV-1 and HSV-2 were no longer detectable, in contrast to the control (water). This confirms the expectation that antiseptics effective in vitro against enveloped viruses are also effective preventively and possibly even therapeutically when used in humans.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10705</offset><text>In stage 1 patients (presymptomatic stage 1–2 d before first symptoms after infection of COVID-19), viral clearance was significantly increased by both 1% PVP-iodine and the combination of ethanol with essential oils compared with tap water on days 4, 6, and 12. Also, in a small case-study in Spain, 1% PVP-iodine decreased the viral load in COVID-19 patients. In a RCT (n=303 for each group) including patients who had a positive PCR on the first symptom day of COVID-19, 1% PVP-iodine solution was applied as a gargling solution and as nasal and eye drops (control lukewarm water) every 4 h for 4 weeks immediately after confirmed diagnosis. In the treatment group, morbidity and mortality were significantly reduced on days 3, 5, and 7. Thyroid hormone levels were not affected.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11490</offset><text>In an intervention study in children age 10 years or older (n=995), with protective measures otherwise identical to those in the control group, 2-month application of PHTALOX 3–5 times/d for 1 min reduced the incidence of COVID-19 by 54% (p=0.076).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11741</offset><text>In a RCT (n=88 each), gargling 3 times daily for 7 d with ß-cyclodextrin Citrox significantly reduced SARS-CoV-2 in saliva in asymptomatic and mild COVID-19 4 h after initial application.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>11930</offset><text>Nasal spray</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11942</offset><text>In colds, carragelose (Algovir® cold spray: 1.2 mg carragelose +0.5% NaCl) significantly reduced both the number of people who fell ill and the duration of illness (3 studies).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>12120</offset><text>2.4 Concluding evaluation of the study situation</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12169</offset><text>HPO and CHG show little or no effectiveness in vitro, which was confirmed clinically. CPC (0.04–0.075%) and essential oils are moderately to highly effective in vitro and also clinically effective. Considering the overall data, PVP-iodine based antiseptics (0.5–1%) are superior to the other agents listed. In the oral cavity, gargle solutions based on essential oils can be assumed to have a comparable effect.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12585</offset><text>Currently, further randomized trials with new active ingredients are being conducted to be able to implement the easily realizable prevention potential of virucidal nasopharyngeal antisepsis in an even more targeted manner.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>12809</offset><text>3. Risk assessment for long-term use</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12846</offset><text>The use of carragelose (red algae extract), saline, green tea, aronia juice, and essential oils is safe without and with the addition of ethanol.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12992</offset><text>1.25 % PVP-iodine is tolerated in the nasal cavity without subjectively disturbing sensations and does not cause inhibition of cilia activity. While PVP-iodine 2.5% causes severe eye burning, the concentration of 1.25% PVP-iodine is tolerated without irritation or damage, does not penetrate the anterior chamber of the eye and does not affect thyroid function,.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13355</offset><text>PVP-iodine’s absorption during gargling has not been investigated. Under the worst case assumption of 10% absorption, a single gargle with 1.25% PVP-iodine would result in the absorption of about 1000 µg of iodine, which is 5 times the daily dietary iodine intake recommended by the WHO. Iodine-induced hyperthyroidism or hypothyroidism have been described in the context of topical applications only with excess exposures many times higher than those possible with gargling. Single case reports are available for urinary bladder or peritoneal irrigation or for irrigation of extensive wounds,,,. In a review, Frank et al. concluded that the use of PVP-iodine in the oral cavity in concentrations of up to 2.5% is safe for up to 5 months.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14098</offset><text>Since March 2020, pre-exposure prophylaxis has been performed at Greifswald University Medicine with 1.25 % PVP-iodine solution and, in case of contraindication, with mouthrinse based on ethanol/essential oils. So far, there has been no sign of incompatibilities.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>14362</offset><text>4. International recommendations and recommendations derived from the evaluation of the current state of knowledge for Germany</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_2</infon><offset>14489</offset><text>4.1 Protection of the population when regional clusters or high incidences of infection become known</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>14590</offset><text>Gargle</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>14597</offset><text>So far, recommendations have only been made for the pandemic situation or in hotspots. However, in view of the decline in the incidence of the disease, it seems reasonable to make recommendations for the endemic situation as well. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>14829</offset><text>Since no commercially available antiseptics with a reduced content of PVP-iodine are available in Germany, suggestions are made for self-preparation by diluting the commercially available oral antiseptic Betaisodona Oral Antiseptic (contains 7.5% v/v PVP-iodine and 36% v/v ethanol). Since the diluted solution is stable for only a short time, dilutions must always be prepared fresh. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15215</offset><text>Preparation 0.23% solution: </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15244</offset><text>Variant A: add 1 teaspoon of Betaisodona Oral Antiseptic to water glass half filled (100 ml) with lukewarm water. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15359</offset><text>Variant B: to prepare a smaller amount, e.g. to fill a spray applicator for application in the nose, 1 teaspoon of mouth antiseptic + 5 teaspoons of water).</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15516</offset><text>Preparation 1.25% solution for pre- or post-exposure prophylaxis:</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15582</offset><text>Variant A: Pharmacy preparation according to New Prescriptions Formulary (NRF 15.13, [66]).</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15674</offset><text>Variant B: Own preparation – add 3 teaspoons of Betaisodona Oral Antiseptic to a water glass half-filled (100 ml) with lukewarm water.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_4</infon><offset>15811</offset><text>Japan</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15817</offset><text>Gargle in the morning and evening with 0.23% PVP-iodine solution.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_4</infon><offset>15883</offset><text>Germany</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>15891</offset><text>Gargle in the morning and evening with the combination of essential oils with ethanol (e.g., Listerine® Cool mint). For people with alcohol intolerance or with mucosal sensitivity, the formulation without alcohol (Listerine® Cool Mint mild flavor) should be used instead of the combination of essential oils with alcohol.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>16215</offset><text>Otherwise healthy children are not at risk from acute SARS-CoV-2 infection (most have a mild disease course or are asymptomatic). Effective gargling is usually possible with some practice only once they have reached school age. Because of the better taste, green tea or aronia juice are more suitable for children.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>16530</offset><text>Nasal cavity </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_4</infon><offset>16544</offset><text>Japan</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>16550</offset><text>Morning and evening spraying with 0.23% PVP-iodine solution into both nostrils with simultaneous inhalation. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_4</infon><offset>16660</offset><text>Germany</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>16668</offset><text>In the absence of a PVP-iodine based nasal spray, use a Carragelose®-based nasal spray (e.g. Algovir® cold spray) in the morning and evening; probably more effective is 0.23% PVP-iodine solution (self-production see above).</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_2</infon><offset>16894</offset><text>4.2 Protection of the community at low risk of infection</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>16951</offset><text>The following recommendations are derived for Germany.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>17006</offset><text>Mouth rinse/gargle</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>17025</offset><text>Rhythm: Morning and evening, 3 times/d if possible, and additionally after eating meals together or other communal activities in elderly-care facilities or in rehabilitation facilities, at family gatherings (to the extent currently permitted), at professional group meetings, in schools and kindergartens, religious services and other religious occasions.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>17381</offset><text>Solutions: Saline solution (preparation: Dissolve level teaspoon of saline in 100 ml of lukewarm water, put about amount of a shot glass in the mouth, interrupt gargling each time before inhaling, repeat process for about 3 min, finally spit out gargling solution). </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>17648</offset><text>Alternatively, gargle with green tea, sage tea (preparation: pour about 3 g sage leaves with 150 ml boiling water, infuse for 10 min, pour tea through strainer, gargle with sage solution while still warm) or mouthwash based on essential oils.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>17891</offset><text>Nasal cavity</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>17904</offset><text>Rhythm: Morning and evening </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>17933</offset><text>Agent: Nasal spray based on Carragelose® (e.g., Algovir® cold spray), if possible, 3 times/d and in addition after eating meals together or other communal activities in elderly-care facilities or in rehabilitation facilities, at family gatherings (to the extent currently permitted), at professional group eetings, in schools and kindergartens, religious services and other religious occasions.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18330</offset><text>Solutions: Saline solution as an unpreserved product and without added decongestants (e.g., Hysan® Salinspray® or Rinupret®). </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18460</offset><text>Alternatively, prepare solution as for gargling (see above) and draw it into the nose by inhalation.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_2</infon><offset>18561</offset><text>4.3 Pre-exposure prophylaxis for the protection of healthcare workers before aerosol producing interventions </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18671</offset><text>Before dental treatment, intubation, rhinoscopy, and bronchoscopy [64, 65], virucidal antisepsis in the oral cavity or vestibule nasi is recommended to reduce the viral load for the duration of the treatment. The patient is instructed to rinse the oral cavity thoroughly, spit out the solution, and then gargle. For nasal access, the use of 1.25% PVP-iodine solution as a spray is additionally recommended.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>19078</offset><text>Belgium</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19086</offset><text>Gargle with 1 % PVP-iodine.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>19114</offset><text>Portugal, Malta</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19130</offset><text>Gargle with 0.2 % PVP-iodine.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>19160</offset><text>World Health Organization </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19187</offset><text>Gargle with 0.2 % PVP-iodine.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_3</infon><offset>19217</offset><text>Germany</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19225</offset><text>Gargling with 1.25% PVP-iodine solution, alternatively an essential oil based mouth rinse. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19317</offset><text>In case of contraindications to iodine (hyperthyroidism, autonomous adenoma of the thyroid gland, iodine allergy), formulations based on essential oils can be considered. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_2</infon><offset>19489</offset><text>4.4 Postexposure prophylaxis</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19518</offset><text>After unprotected known contact with SARS-CoV-2-positive for 14 d 1.25% PVP-iodine solution; if iodine is contraindicated, gargling with mouth wash based on essential oils with or without content of ethanol + nasal spray with 1.25% PVP-iodine solution (own production see above); hypochlorite-based nasal spray (e.g. Plasma Liquid nasal spray gel).</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19867</offset><text>After eye contamination, rinse once with 1.25% PVP-Iodine solution. </text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19936</offset><text>After accidental injury with risk of infection by SARS-C0V-2 PVP-I as alcoholic formulation (e.g. Braunoderm® or Betaseptic®).</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>20065</offset><text>Notes</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_2</infon><offset>20071</offset><text>Competing interests</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>20091</offset><text>The authors declare that they have no competing interests.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>20150</offset><text>Erratum</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>20158</offset><text>Affiliation update Peter Walger</text></passage><passage><infon key="fpage">P659</infon><infon key="issue">7</infon><infon key="lpage">P661</infon><infon key="name_0">surname:Abrams;given-names:EM</infon><infon key="name_1">surname:Szefler;given-names:SJ</infon><infon key="pub-id_doi">10.1016/S2213-2600(20)30234-4</infon><infon key="section_type">REF</infon><infon key="source">Lancet Respir Med</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2020</infon><offset>20190</offset><text>COVID-19 and the impact of social determinants of health</text></passage><passage><infon key="comment">Available from: cited 2022 Feb 22</infon><infon key="name_0">surname:Deopa;given-names:N</infon><infon key="name_1">surname:Fortunato;given-names:P</infon><infon key="section_type">REF</infon><infon key="series">UNCTAD Research Paper No. 49. UNCTAD/SER.RP/2020/8</infon><infon key="source">Coronagraben. Culture and Social Distancing in Times of COVID-19. UNCTAD Research Paper No. 49. UNCTAD/SER.RP/2020/8</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>20247</offset></passage><passage><infon key="fpage">143</infon><infon key="issue">1</infon><infon key="name_0">surname:Firouzbakht;given-names:M</infon><infon key="name_1">surname:Omidvar;given-names:S</infon><infon key="name_2">surname:Firouzbakht;given-names:S</infon><infon key="name_3">surname:Asadi-Amoli;given-names:A</infon><infon key="pub-id_doi">10.1186/s12889-021-10201-4</infon><infon key="pub-id_pmid">33451303</infon><infon key="section_type">REF</infon><infon key="source">BMC Public Health</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2021</infon><offset>20248</offset><text>COVID-19 preventive behaviors and influencing factors in the Iranian population; a web-based survey</text></passage><passage><infon key="fpage">e0261869</infon><infon key="issue">1</infon><infon key="name_0">surname:Akther;given-names:T</infon><infon key="name_1">surname:Nur;given-names:T</infon><infon key="pub-id_doi">10.1371/journal.pone.0261869</infon><infon key="pub-id_pmid">35020764</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2022</infon><offset>20348</offset><text>A model of factors influencing COVID-19 vaccine acceptance: A synthesis of the theory of reasoned action, conspiracy theory belief, awareness, perceived usefulness, and perceived ease of use</text></passage><passage><infon key="issue">16</infon><infon key="name_0">surname:Sun;given-names:Z</infon><infon key="name_1">surname:Yang;given-names:B</infon><infon key="name_2">surname:Zhang;given-names:R</infon><infon key="name_3">surname:Cheng;given-names:X</infon><infon key="pub-id_doi">10.3390/ijerph17165889</infon><infon key="section_type">REF</infon><infon key="source">Int J Environ Res Public Health</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2020</infon><offset>20539</offset><text>Influencing Factors of Understanding COVID-19 Risks and Coping Behaviors among the Elderly Population</text></passage><passage><infon key="fpage">894</infon><infon key="issue">1</infon><infon key="lpage">947</infon><infon key="name_0">surname:Carro;given-names:B</infon><infon key="pub-id_doi">10.1080/26895293.2021.1977186</infon><infon key="section_type">REF</infon><infon key="source">All Life</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2021</infon><offset>20641</offset><text>SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey</text></passage><passage><infon key="fpage">892</infon><infon key="issue">5</infon><infon key="lpage">903</infon><infon key="name_0">surname:Huang;given-names:N</infon><infon key="name_1">surname:Pérez;given-names:P</infon><infon key="name_10">surname:Pelayo;given-names:E</infon><infon key="name_11">surname:Maldonado;given-names:JO</infon><infon key="name_12">surname:Lafont;given-names:BA</infon><infon key="name_13">surname:Jang;given-names:SI</infon><infon key="name_14">surname:Nasir;given-names:N</infon><infon key="name_15">surname:Padilla;given-names:RJ</infon><infon key="name_16">surname:Murrah;given-names:VA</infon><infon key="name_17">surname:Maile;given-names:R</infon><infon key="name_18">surname:Lovell;given-names:W</infon><infon key="name_19">surname:Wallet;given-names:SM</infon><infon key="name_2">surname:Kato;given-names:T</infon><infon key="name_20">surname:Bowman;given-names:NM</infon><infon key="name_21">surname:Meinig;given-names:SL</infon><infon key="name_22">surname:Wolfgang;given-names:MC</infon><infon key="name_23">surname:Choudhury;given-names:SN</infon><infon key="name_24">surname:Novotny;given-names:M</infon><infon key="name_25">surname:Aevermann;given-names:BD</infon><infon key="name_26">surname:Scheuermann;given-names:RH</infon><infon key="name_27">surname:Cannon;given-names:G</infon><infon key="name_28">surname:Anderson;given-names:CW</infon><infon key="name_29">surname:Lee;given-names:RE</infon><infon key="name_3">surname:Mikami;given-names:Y</infon><infon key="name_30">surname:Marchesan;given-names:JT</infon><infon key="name_31">surname:Bush;given-names:M</infon><infon key="name_32">surname:Freire;given-names:M</infon><infon key="name_33">surname:Kimple;given-names:AJ</infon><infon key="name_34">surname:Herr;given-names:DL</infon><infon key="name_35">surname:Rabin;given-names:J</infon><infon key="name_36">surname:Grazioli;given-names:A</infon><infon key="name_37">surname:Das;given-names:S</infon><infon key="name_38">surname:French;given-names:BN</infon><infon key="name_39">surname:Pranzatelli;given-names:T</infon><infon key="name_4">surname:Okuda;given-names:K</infon><infon key="name_40">surname:Chiorini;given-names:JA</infon><infon key="name_41">surname:Kleiner;given-names:DE</infon><infon key="name_42">surname:Pittaluga;given-names:S</infon><infon key="name_43">surname:Hewitt;given-names:SM</infon><infon key="name_44">surname:Burbelo;given-names:PD</infon><infon key="name_45">surname:Chertow;given-names:D</infon><infon key="name_5">surname:Gilmore;given-names:RC</infon><infon key="name_6">surname:Conde;given-names:CD</infon><infon key="name_7">surname:Gasmi;given-names:B</infon><infon key="name_8">surname:Stein;given-names:S</infon><infon key="name_9">surname:Beach;given-names:M</infon><infon key="pub-id_doi">10.1038/s41591-021-01296-8</infon><infon key="pub-id_pmid">33767405</infon><infon key="section_type">REF</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2021</infon><offset>20763</offset><text>SARS-CoV-2 infection of the oral cavity and saliva</text></passage><passage><infon key="fpage">472</infon><infon key="issue">15</infon><infon key="lpage">476</infon><infon key="name_0">surname:Heinzerling;given-names:A</infon><infon key="name_1">surname:Stuckey;given-names:MJ</infon><infon key="name_10">surname:Epson;given-names:E</infon><infon key="name_2">surname:Scheuer;given-names:T</infon><infon key="name_3">surname:Xu;given-names:K</infon><infon key="name_4">surname:Perkins;given-names:KM</infon><infon key="name_5">surname:Resseger;given-names:H</infon><infon key="name_6">surname:Magill;given-names:S</infon><infon key="name_7">surname:Verani;given-names:JR</infon><infon key="name_8">surname:Jain;given-names:S</infon><infon key="name_9">surname:Acosta;given-names:M</infon><infon key="pub-id_doi">10.15585/mmwr.mm6915e5</infon><infon key="pub-id_pmid">32298249</infon><infon key="section_type">REF</infon><infon key="source">MMWR Morb Mortal Wkly Rep</infon><infon key="type">ref</infon><infon key="volume">69</infon><infon key="year">2020</infon><offset>20814</offset><text>Transmission of COVID-19 to Health Care Personnel During Exposures to a Hospitalized Patient - Solano County, California, February 2020</text></passage><passage><infon key="name_0">surname:Mohamed;given-names:NA</infon><infon key="name_1">surname:Baharom;given-names:N</infon><infon key="name_10">surname:Sugumar;given-names:ANK</infon><infon key="name_11">surname:Mohammad Kazmin;given-names:NE</infon><infon key="name_12">surname:Cheong;given-names:XK</infon><infon key="name_13">surname:Saniman;given-names:SM</infon><infon key="name_14">surname:Isahak;given-names:I</infon><infon key="name_2">surname:Shahida;given-names:W</infon><infon key="name_3">surname:Zainol Rashid;given-names:Z</infon><infon key="name_4">surname:Wong;given-names:KK</infon><infon key="name_5">surname:Ali;given-names:UK</infon><infon key="name_6">surname:Othman;given-names:SN</infon><infon key="name_7">surname:Abd Samad;given-names:MN</infon><infon key="name_8">surname:Kori;given-names:N</infon><infon key="name_9">surname:Periyasamy;given-names:P</infon><infon key="pub-id_doi">10.1101/2020.09.07.20180448</infon><infon key="section_type">REF</infon><infon key="source">medRxiv</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>20950</offset><text>Early viral clearance among covid-19 patients when gargling with povidone-iodine and essential oils: a pilot clinical trial [Preprint]</text></passage><passage><infon key="fpage">66</infon><infon key="issue">4</infon><infon key="lpage">75</infon><infon key="name_0">surname:Raoult;given-names:D</infon><infon key="name_1">surname:Zumla;given-names:A</infon><infon key="name_2">surname:Locatelli;given-names:F</infon><infon key="name_3">surname:Ippolito;given-names:G</infon><infon key="name_4">surname:Kroemer;given-names:G</infon><infon key="pub-id_doi">10.15698/cst2020.04.216</infon><infon key="pub-id_pmid">32292881</infon><infon key="section_type">REF</infon><infon key="source">Cell Stress</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2020</infon><offset>21085</offset><text>Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses</text></passage><passage><infon key="fpage">919</infon><infon key="issue">1</infon><infon key="lpage">923</infon><infon key="name_0">surname:Choudhury;given-names:MIM</infon><infon key="name_1">surname:Shabnam;given-names:N</infon><infon key="name_2">surname:Ahsan;given-names:T</infon><infon key="name_3">surname:Kabir;given-names:MS</infon><infon key="name_4">surname:Md Khan;given-names:R</infon><infon key="name_5">surname:Ahsan;given-names:SA</infon><infon key="pub-id_doi">10.3329/brc.v7i1.54245</infon><infon key="section_type">REF</infon><infon key="source">Biores Comm</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2021</infon><offset>21177</offset><text>Effect of 1% povidone iodine mouthwash/gargle, nasal and eye drop in COVID -19 patient</text></passage><passage><infon key="name_0">surname:Fangerau;given-names:H</infon><infon key="name_1">surname:Labisch;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">Pest und Corona. Pandemie in Geschichte, Gegenwart und Zukunft</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>21264</offset></passage><passage><infon key="fpage">1</infon><infon key="issue">9</infon><infon key="lpage">9</infon><infon key="name_0">surname:Kramer;given-names:A</infon><infon key="name_1">surname:Eggers;given-names:M</infon><infon key="section_type">REF</infon><infon key="source">Hyg Med</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">2020</infon><offset>21265</offset><text>Prevention of respiratory viral infections by virucidal mucosal antisepsis among medical staff and in the community</text></passage><passage><infon key="name_0">surname:Klimpel;given-names:GR</infon><infon key="name_1">surname:Baron;given-names:S</infon><infon key="section_type">REF</infon><infon key="source">Medical Microbiology</infon><infon key="type">ref</infon><infon key="year">1996</infon><offset>21381</offset><text>Immune Defenses</text></passage><passage><infon key="fpage">10905</infon><infon key="issue">22</infon><infon key="lpage">10910</infon><infon key="name_0">surname:Kudo;given-names:E</infon><infon key="name_1">surname:Song;given-names:E</infon><infon key="name_2">surname:Yockey;given-names:LJ</infon><infon key="name_3">surname:Rakib;given-names:T</infon><infon key="name_4">surname:Wong;given-names:PW</infon><infon key="name_5">surname:Homer;given-names:RJ</infon><infon key="name_6">surname:Iwasaki;given-names:A</infon><infon key="pub-id_doi">10.1073/pnas.1902840116</infon><infon key="pub-id_pmid">31085641</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">116</infon><infon key="year">2019</infon><offset>21397</offset><text>Low ambient humidity impairs barrier function and innate resistance against influenza infection</text></passage><passage><infon key="fpage">669</infon><infon key="issue">3</infon><infon key="lpage">675</infon><infon key="name_0">surname:Anderson;given-names:DE</infon><infon key="name_1">surname:Sivalingam;given-names:V</infon><infon key="name_2">surname:Kang;given-names:AEZ</infon><infon key="name_3">surname:Ananthanarayanan;given-names:A</infon><infon key="name_4">surname:Arumugam;given-names:H</infon><infon key="name_5">surname:Jenkins;given-names:TM</infon><infon key="name_6">surname:Hadjiat;given-names:Y</infon><infon key="name_7">surname:Eggers;given-names:M</infon><infon key="pub-id_doi">10.1007/s40121-020-00316-3</infon><infon key="pub-id_pmid">32643111</infon><infon key="section_type">REF</infon><infon key="source">Infect Dis Ther</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2020</infon><offset>21493</offset><text>Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">4</infon><infon key="name_0">surname:Hassandarvish;given-names:P</infon><infon key="name_1">surname:Tiong;given-names:V</infon><infon key="name_2">surname:Mohamed;given-names:NA</infon><infon key="name_3">surname:Arumugam;given-names:H</infon><infon key="name_4">surname:Ananthanarayanan;given-names:A</infon><infon key="name_5">surname:Qasuri;given-names:M</infon><infon key="name_6">surname:Hadjiat;given-names:Y</infon><infon key="name_7">surname:Abubakar;given-names:S</infon><infon key="pub-id_doi">10.1038/s41415-020-2402-0</infon><infon key="section_type">REF</infon><infon key="source">Br Dent J</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>21611</offset><text>In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice</text></passage><passage><infon key="fpage">269</infon><infon key="lpage">274</infon><infon key="name_0">surname:Santos;given-names:C</infon><infon key="name_1">surname:da Fonseca Orcina;given-names:B</infon><infon key="name_2">surname:Brito Reia;given-names:VC</infon><infon key="name_3">surname:Ribeiro;given-names:LG</infon><infon key="name_4">surname:Grotto;given-names:RMT</infon><infon key="name_5">surname:Prudenciatti;given-names:A</infon><infon key="name_6">surname:de Moraes;given-names:LN</infon><infon key="name_7">surname:Ragghianti Zangrando;given-names:M</infon><infon key="name_8">surname:Vilhena;given-names:FV</infon><infon key="name_9">surname:da Silva Santos;given-names:PS</infon><infon key="pub-id_doi">10.2147/CCIDE.S315419</infon><infon key="section_type">REF</infon><infon key="source">Clin Cosmet Investig Dent</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2021</infon><offset>21732</offset><text>Virucidal Activity of the Antiseptic Mouthwash and Dental Gel Containing Anionic Phthalocyanine Derivative: In vitro Study</text></passage><passage><infon key="fpage">Doc03</infon><infon key="name_0">surname:da Fonseca Orcina;given-names:B</infon><infon key="name_1">surname:Reia;given-names:VCB</infon><infon key="name_2">surname:Simão;given-names:ANC</infon><infon key="name_3">surname:Lonni;given-names:AASG</infon><infon key="name_4">surname:Fernandes;given-names:TMF</infon><infon key="name_5">surname:Poleti;given-names:ML</infon><infon key="name_6">surname:Vilhena;given-names:FV</infon><infon key="name_7">surname:da Silva Santos;given-names:PS</infon><infon key="pub-id_doi">10.3205/dgkh000406</infon><infon key="pub-id_pmid">35284205</infon><infon key="section_type">REF</infon><infon key="source">GMS Hyg Infect Control</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2022</infon><offset>21855</offset><text>A recommendation of PHTALOX® for preventing infection and progression of COVID-19: a 1-year summarized update of scientific approaches</text></passage><passage><infon key="fpage">9</infon><infon key="lpage">13</infon><infon key="name_0">surname:Meister;given-names:TL</infon><infon key="name_1">surname:Todt;given-names:D</infon><infon key="name_2">surname:Brüggemann;given-names:Y</infon><infon key="name_3">surname:Steinmann;given-names:J</infon><infon key="name_4">surname:Banava;given-names:S</infon><infon key="name_5">surname:Brill;given-names:FHH</infon><infon key="name_6">surname:Steinmann;given-names:J</infon><infon key="name_7">surname:Pfaender;given-names:S</infon><infon key="name_8">surname:Steinmann;given-names:E</infon><infon key="pub-id_doi">10.1016/j.jhin.2021.10.019</infon><infon key="pub-id_pmid">34752803</infon><infon key="section_type">REF</infon><infon key="source">J Hosp Infect</infon><infon key="type">ref</infon><infon key="volume">120</infon><infon key="year">2022</infon><offset>21991</offset><text>Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2</text></passage><passage><infon key="name_0">surname:Pelletier;given-names:JS</infon><infon key="name_1">surname:Tessema;given-names:B</infon><infon key="name_2">surname:Frank;given-names:S</infon><infon key="name_3">surname:Westover;given-names:JB</infon><infon key="name_4">surname:Brown;given-names:SM</infon><infon key="name_5">surname:Capriotti;given-names:JA</infon><infon key="pub-id_doi">10.1177/0145561320957237</infon><infon key="section_type">REF</infon><infon key="source">Ear Nose Throat J</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>22082</offset><text>Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key="name_0">surname:Statkute;given-names:E</infon><infon key="name_1">surname:Rubina;given-names:A</infon><infon key="name_2">surname:O’Donnell;given-names:VB</infon><infon key="name_3">surname:Thomas;given-names:DW</infon><infon key="name_4">surname:Stanton;given-names:RJ</infon><infon key="pub-id_doi">10.1101/2020.11.13.381079</infon><infon key="section_type">REF</infon><infon key="source">bioRxiv</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>22218</offset><text>Brief report: the virucidal efficacy of oral rinse components against sars-cov-2 in vitro [Preprint]</text></passage><passage><infon key="fpage">648547</infon><infon key="name_0">surname:Ather;given-names:A</infon><infon key="name_1">surname:Parolia;given-names:A</infon><infon key="name_2">surname:Ruparel;given-names:NB</infon><infon key="pub-id_doi">10.3389/fdmed.2021.648547</infon><infon key="section_type">REF</infon><infon key="source">Front Dent Med</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2021</infon><offset>22319</offset><text>Efficacy of mouth rinses against SARS-CoV-2: a scoping review</text></passage><passage><infon key="fpage">39</infon><infon key="lpage">45</infon><infon key="name_0">surname:Chopra;given-names:A</infon><infon key="name_1">surname:Sivaraman;given-names:K</infon><infon key="name_2">surname:Radhakrishnan;given-names:R</infon><infon key="name_3">surname:Balakrishnan;given-names:D</infon><infon key="name_4">surname:Narayana;given-names:A</infon><infon key="pub-id_doi">10.1016/j.jdsr.2021.03.001</infon><infon key="pub-id_pmid">33747261</infon><infon key="section_type">REF</infon><infon key="source">Jpn Dent Sci Rev</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2021</infon><offset>22381</offset><text>Can povidone iodine gargle/mouthrinse inactivate SARS-CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update</text></passage><passage><infon key="issue">4</infon><infon key="name_0">surname:Davies;given-names:K</infon><infon key="name_1">surname:Buczkowski;given-names:H</infon><infon key="name_2">surname:Welch;given-names:SR</infon><infon key="name_3">surname:Green;given-names:N</infon><infon key="name_4">surname:Mawer;given-names:D</infon><infon key="name_5">surname:Woodford;given-names:N</infon><infon key="name_6">surname:Roberts;given-names:ADG</infon><infon key="name_7">surname:Nixon;given-names:PJ</infon><infon key="name_8">surname:Seymour;given-names:DW</infon><infon key="name_9">surname:Killip;given-names:MJ</infon><infon key="pub-id_doi">10.1099/jgv.0.001578</infon><infon key="section_type">REF</infon><infon key="source">J Gen Virol</infon><infon key="type">ref</infon><infon key="volume">102</infon><infon key="year">2021</infon><offset>22559</offset><text>Effective inactivation of SARS-CoV-2 by commercially available mouthwashes</text></passage><passage><infon key="issue">3</infon><infon key="name_0">surname:Koch-Heier;given-names:J</infon><infon key="name_1">surname:Hoffmann;given-names:H</infon><infon key="name_2">surname:Schindler;given-names:M</infon><infon key="name_3">surname:Lussi;given-names:A</infon><infon key="name_4">surname:Planz;given-names:O</infon><infon key="pub-id_doi">10.3390/microorganisms9030521</infon><infon key="section_type">REF</infon><infon key="source">Microorganisms</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2021</infon><offset>22634</offset><text>Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX and BacterX Pro</text></passage><passage><infon key="fpage">475</infon><infon key="issue">4</infon><infon key="lpage">477</infon><infon key="name_0">surname:Komine;given-names:A</infon><infon key="name_1">surname:Yamaguchi;given-names:E</infon><infon key="name_2">surname:Okamoto;given-names:N</infon><infon key="name_3">surname:Yamamoto;given-names:K</infon><infon key="pub-id_doi">10.1016/j.ajoms.2021.02.002</infon><infon key="pub-id_pmid">33643836</infon><infon key="section_type">REF</infon><infon key="source">J Oral Maxillofac Surg Med Pathol</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">2021</infon><offset>22737</offset><text>Virucidal activity of oral care products against SARS-CoV-2</text></passage><passage><infon key="fpage">1265</infon><infon key="issue">11</infon><infon key="lpage">1272</infon><infon key="name_0">surname:Muñoz-Basagoiti;given-names:J</infon><infon key="name_1">surname:Perez-Zsolt;given-names:D</infon><infon key="name_10">surname:Clotet;given-names:B</infon><infon key="name_11">surname:Izquierdo-Useros;given-names:N</infon><infon key="name_2">surname:León;given-names:R</infon><infon key="name_3">surname:Blanc;given-names:V</infon><infon key="name_4">surname:Raïch-Regué;given-names:D</infon><infon key="name_5">surname:Cano-Sarabia;given-names:M</infon><infon key="name_6">surname:Trinité;given-names:B</infon><infon key="name_7">surname:Pradenas;given-names:E</infon><infon key="name_8">surname:Blanco;given-names:J</infon><infon key="name_9">surname:Gispert;given-names:J</infon><infon key="pub-id_doi">10.1177/00220345211029269</infon><infon key="pub-id_pmid">34282982</infon><infon key="section_type">REF</infon><infon key="source">J Dent Res</infon><infon key="type">ref</infon><infon key="volume">100</infon><infon key="year">2021</infon><offset>22797</offset><text>Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro</text></passage><passage><infon key="fpage">180</infon><infon key="lpage">183</infon><infon key="name_0">surname:Steinhauer;given-names:K</infon><infon key="name_1">surname:Meister;given-names:TL</infon><infon key="name_10">surname:Steinmann;given-names:E</infon><infon key="name_2">surname:Todt;given-names:D</infon><infon key="name_3">surname:Krawczyk;given-names:A</infon><infon key="name_4">surname:Paßvogel;given-names:L</infon><infon key="name_5">surname:Becker;given-names:B</infon><infon key="name_6">surname:Paulmann;given-names:D</infon><infon key="name_7">surname:Bischoff;given-names:B</infon><infon key="name_8">surname:Pfaender;given-names:S</infon><infon key="name_9">surname:Brill;given-names:FHH</infon><infon key="pub-id_doi">10.1016/j.jhin.2021.01.031</infon><infon key="pub-id_pmid">33582201</infon><infon key="section_type">REF</infon><infon key="source">J Hosp Infect</infon><infon key="type">ref</infon><infon key="volume">111</infon><infon key="year">2021</infon><offset>22873</offset><text>Comparison of the in-vitro efficacy of different mouthwash solutions targeting SARS-CoV-2 based on the European Standard EN 14476</text></passage><passage><infon key="fpage">1179</infon><infon key="issue">9</infon><infon key="lpage">1185</infon><infon key="name_0">surname:Tadakamadla;given-names:J</infon><infon key="name_1">surname:Boccalari;given-names:E</infon><infon key="name_2">surname:Rathore;given-names:V</infon><infon key="name_3">surname:Dolci;given-names:C</infon><infon key="name_4">surname:Tartaglia;given-names:GM</infon><infon key="name_5">surname:Tadakamadla;given-names:SK</infon><infon key="pub-id_doi">10.1016/j.jiph.2021.07.020</infon><infon key="pub-id_pmid">34399189</infon><infon key="section_type">REF</infon><infon key="source">J Infect Public Health</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2021</infon><offset>23003</offset><text>In vitro studies evaluating the efficacy of mouth rinses on Sars-Cov-2: A systematic review</text></passage><passage><infon key="issue">3</infon><infon key="name_0">surname:Xu;given-names:C</infon><infon key="name_1">surname:Wang;given-names:A</infon><infon key="name_2">surname:Hoskin;given-names:ER</infon><infon key="name_3">surname:Cugini;given-names:C</infon><infon key="name_4">surname:Markowitz;given-names:K</infon><infon key="name_5">surname:Chang;given-names:TL</infon><infon key="name_6">surname:Fine;given-names:DH</infon><infon key="pub-id_doi">10.3390/pathogens10030272</infon><infon key="section_type">REF</infon><infon key="source">Pathogens</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2021</infon><offset>23095</offset><text>Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro</text></passage><passage><infon key="name_0">surname:Mendoza;given-names:JPIM</infon><infon key="name_1">surname:Ubillús;given-names:BPT</infon><infon key="name_2">surname:Bolívar;given-names:GTS</infon><infon key="name_3">surname:Palacios;given-names:RDPC</infon><infon key="name_4">surname:Lopez;given-names:PSGH</infon><infon key="name_5">surname:Rodríguez;given-names:DAP</infon><infon key="name_6">surname:Koecklin;given-names:KHU</infon><infon key="pub-id_doi">10.1016/j.sdentj.2022.01.006</infon><infon key="section_type">REF</infon><infon key="source">Saudi Dent J</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>23178</offset><text>Antiviral effect of mouthwashes against SARS-COV-2: A systematic review</text></passage><passage><infon key="fpage">529</infon><infon key="issue">6</infon><infon key="lpage">533</infon><infon key="name_0">surname:Bidra;given-names:AS</infon><infon key="name_1">surname:Pelletier;given-names:JS</infon><infon key="name_2">surname:Westover;given-names:JB</infon><infon key="name_3">surname:Frank;given-names:S</infon><infon key="name_4">surname:Brown;given-names:SM</infon><infon key="name_5">surname:Tessema;given-names:B</infon><infon key="pub-id_doi">10.1111/jopr.13209</infon><infon key="pub-id_pmid">32511851</infon><infon key="section_type">REF</infon><infon key="source">J Prosthodont</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2020</infon><offset>23250</offset><text>Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse</text></passage><passage><infon key="fpage">1289</infon><infon key="issue">8</infon><infon key="lpage">1292</infon><infon key="name_0">surname:Meister;given-names:TL</infon><infon key="name_1">surname:Brüggemann;given-names:Y</infon><infon key="name_10">surname:Pfaender;given-names:S</infon><infon key="name_11">surname:Steinmann;given-names:E</infon><infon key="name_2">surname:Todt;given-names:D</infon><infon key="name_3">surname:Conzelmann;given-names:C</infon><infon key="name_4">surname:Müller;given-names:JA</infon><infon key="name_5">surname:Groß;given-names:R</infon><infon key="name_6">surname:Münch;given-names:J</infon><infon key="name_7">surname:Krawczyk;given-names:A</infon><infon key="name_8">surname:Steinmann;given-names:J</infon><infon key="name_9">surname:Steinmann;given-names:J</infon><infon key="pub-id_doi">10.1093/infdis/jiaa471</infon><infon key="pub-id_pmid">32726430</infon><infon key="section_type">REF</infon><infon key="source">J Infect Dis</infon><infon key="type">ref</infon><infon key="volume">222</infon><infon key="year">2020</infon><offset>23386</offset><text>Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2</text></passage><passage><infon key="fpage">305</infon><infon key="issue">2</infon><infon key="lpage">311</infon><infon key="name_0">surname:Seneviratne;given-names:CJ</infon><infon key="name_1">surname:Balan;given-names:P</infon><infon key="name_10">surname:Goh;given-names:BT</infon><infon key="name_11">surname:Sim;given-names:XYJ</infon><infon key="name_2">surname:Ko;given-names:KKK</infon><infon key="name_3">surname:Udawatte;given-names:NS</infon><infon key="name_4">surname:Lai;given-names:D</infon><infon key="name_5">surname:Ng;given-names:DHL</infon><infon key="name_6">surname:Venkatachalam;given-names:I</infon><infon key="name_7">surname:Lim;given-names:KS</infon><infon key="name_8">surname:Ling;given-names:ML</infon><infon key="name_9">surname:Oon;given-names:L</infon><infon key="pub-id_doi">10.1007/s15010-020-01563-9</infon><infon key="pub-id_pmid">33315181</infon><infon key="section_type">REF</infon><infon key="source">Infection</infon><infon key="type">ref</infon><infon key="volume">49</infon><infon key="year">2021</infon><offset>23486</offset><text>Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore</text></passage><passage><infon key="fpage">20502</infon><infon key="issue">1</infon><infon key="name_0">surname:Tiong;given-names:V</infon><infon key="name_1">surname:Hassandarvish;given-names:P</infon><infon key="name_2">surname:Bakar;given-names:SA</infon><infon key="name_3">surname:Mohamed;given-names:NA</infon><infon key="name_4">surname:Wan Sulaiman;given-names:WS</infon><infon key="name_5">surname:Baharom;given-names:N</infon><infon key="name_6">surname:Abdul Samad;given-names:FN</infon><infon key="name_7">surname:Isahak;given-names:I</infon><infon key="pub-id_doi">10.1038/s41598-021-99866-w</infon><infon key="pub-id_pmid">34654867</infon><infon key="section_type">REF</infon><infon key="source">Sci Rep</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2021</infon><offset>23596</offset><text>The effectiveness of various gargle formulations and salt water against SARS-CoV-2</text></passage><passage><infon key="name_0">surname:Conzelmann;given-names:C</infon><infon key="name_1">surname:Weil;given-names:T</infon><infon key="name_2">surname:Groß;given-names:R</infon><infon key="name_3">surname:Jungke;given-names:P</infon><infon key="name_4">surname:Frank;given-names:B</infon><infon key="name_5">surname:Eggers;given-names:M</infon><infon key="name_6">surname:Müller;given-names:JA</infon><infon key="name_7">surname:Münch;given-names:J</infon><infon key="pub-id_doi">10.1101/2020.10.30.360545</infon><infon key="section_type">REF</infon><infon key="source">bioRxiv</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>23679</offset><text>Antiviral activity of plant juices and green tea against SARS-CoV-2 and influenza virus in vitro [Preprint]</text></passage><passage><infon key="fpage">9</infon><infon key="lpage">13</infon><infon key="name_0">surname:Meister;given-names:TL</infon><infon key="name_1">surname:Todt;given-names:D</infon><infon key="name_2">surname:Brüggemann;given-names:Y</infon><infon key="name_3">surname:Steinmann;given-names:J</infon><infon key="name_4">surname:Banava;given-names:S</infon><infon key="name_5">surname:Brill;given-names:FHH</infon><infon key="name_6">surname:Steinmann;given-names:J</infon><infon key="name_7">surname:Pfaender;given-names:S</infon><infon key="name_8">surname:Steinmann;given-names:E</infon><infon key="pub-id_doi">10.1016/j.jhin.2021.10.019</infon><infon key="pub-id_pmid">34752803</infon><infon key="section_type">REF</infon><infon key="source">J Hosp Infect</infon><infon key="type">ref</infon><infon key="volume">120</infon><infon key="year">2022</infon><offset>23787</offset><text>Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2</text></passage><passage><infon key="fpage">908</infon><infon key="lpage">911</infon><infon key="name_0">surname:Martínez Lamas;given-names:L</infon><infon key="name_1">surname:Diz Dios;given-names:P</infon><infon key="name_2">surname:Pérez Rodríguez;given-names:MT</infon><infon key="name_3">surname:Del Campo Pérez;given-names:V</infon><infon key="name_4">surname:Cabrera Alvargonzalez;given-names:JJ</infon><infon key="name_5">surname:López Domínguez;given-names:AM</infon><infon key="name_6">surname:Fernandez Feijoo;given-names:J</infon><infon key="name_7">surname:Diniz Freitas;given-names:M</infon><infon key="name_8">surname:Limeres Posse;given-names:J</infon><infon key="pub-id_doi">10.1111/odi.13526</infon><infon key="pub-id_pmid">32615642</infon><infon key="section_type">REF</infon><infon key="source">Oral Dis</infon><infon key="type">ref</infon><infon key="volume">28 Suppl 1</infon><infon key="year">2022</infon><offset>23878</offset><text>Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests</text></passage><passage><infon key="fpage">3707</infon><infon key="issue">10</infon><infon key="lpage">3713</infon><infon key="name_0">surname:Gottsauner;given-names:MJ</infon><infon key="name_1">surname:Michaelides;given-names:I</infon><infon key="name_10">surname:Vielsmeier;given-names:V</infon><infon key="name_11">surname:Cieplik;given-names:F</infon><infon key="name_2">surname:Schmidt;given-names:B</infon><infon key="name_3">surname:Scholz;given-names:KJ</infon><infon key="name_4">surname:Buchalla;given-names:W</infon><infon key="name_5">surname:Widbiller;given-names:M</infon><infon key="name_6">surname:Hitzenbichler;given-names:F</infon><infon key="name_7">surname:Ettl;given-names:T</infon><infon key="name_8">surname:Reichert;given-names:TE</infon><infon key="name_9">surname:Bohr;given-names:C</infon><infon key="pub-id_doi">10.1007/s00784-020-03549-1</infon><infon key="section_type">REF</infon><infon key="source">Clin Oral Investig</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2020</infon><offset>23957</offset><text>A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2</text></passage><passage><infon key="fpage">27</infon><infon key="issue">11</infon><infon key="lpage">32</infon><infon key="name_0">surname:Avhad;given-names:S</infon><infon key="name_1">surname:Bhanushali;given-names:M</infon><infon key="name_2">surname:Sachdev;given-names:S</infon><infon key="name_3">surname:Save;given-names:S</infon><infon key="name_4">surname:Kalra;given-names:D</infon><infon key="name_5">surname:Dn;given-names:K</infon><infon key="pub-id_doi">10.37506/ijphrd.v11i11.11343</infon><infon key="section_type">REF</infon><infon key="source">Indian J Publ Health Res Dev</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">2020</infon><offset>24083</offset><text>Comparison of effectiveness of chlorine dioxide mouthwash and chlorhexidine gluconate mouthwash in reduction of oral viral load in patients with covid-19</text></passage><passage><infon key="fpage">e07346</infon><infon key="issue">6</infon><infon key="name_0">surname:Eduardo;given-names:FP</infon><infon key="name_1">surname:Corrêa;given-names:L</infon><infon key="name_10">surname:Rebello Pinho;given-names:JR</infon><infon key="name_11">surname:Bezinelli;given-names:LM</infon><infon key="name_2">surname:Heller;given-names:D</infon><infon key="name_3">surname:Daep;given-names:CA</infon><infon key="name_4">surname:Benitez;given-names:C</infon><infon key="name_5">surname:Malheiros;given-names:Z</infon><infon key="name_6">surname:Stewart;given-names:B</infon><infon key="name_7">surname:Ryan;given-names:M</infon><infon key="name_8">surname:Machado;given-names:CM</infon><infon key="name_9">surname:Hamerschlak;given-names:N</infon><infon key="pub-id_doi">10.1016/j.heliyon.2021.e07346</infon><infon key="pub-id_pmid">34189331</infon><infon key="section_type">REF</infon><infon key="source">Heliyon</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2021</infon><offset>24237</offset><text>Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial</text></passage><passage><infon key="fpage">903</infon><infon key="issue">11</infon><infon key="lpage">908</infon><infon key="name_0">surname:Chaudhary;given-names:P</infon><infon key="name_1">surname:Melkonyan;given-names:A</infon><infon key="name_10">surname:Chaney;given-names:M</infon><infon key="name_11">surname:Chase;given-names:H</infon><infon key="name_12">surname:Hermel;given-names:R</infon><infon key="name_13">surname:McClement;given-names:M</infon><infon key="name_14">surname:Sesson;given-names:C</infon><infon key="name_15">surname:Woolsey;given-names:B</infon><infon key="name_16">surname:Kumar;given-names:P</infon><infon key="name_2">surname:Meethil;given-names:A</infon><infon key="name_3">surname:Saraswat;given-names:S</infon><infon key="name_4">surname:Hall;given-names:DL</infon><infon key="name_5">surname:Cottle;given-names:J</infon><infon key="name_6">surname:Wenzel;given-names:M</infon><infon key="name_7">surname:Ayouty;given-names:N</infon><infon key="name_8">surname:Bense;given-names:S</infon><infon key="name_9">surname:Casanova;given-names:F</infon><infon key="pub-id_doi">10.1016/j.adaj.2021.05.021</infon><infon key="pub-id_pmid">34561086</infon><infon key="section_type">REF</infon><infon key="source">J Am Dent Assoc</infon><infon key="type">ref</infon><infon key="volume">152</infon><infon key="year">2021</infon><offset>24326</offset><text>Estimating salivary carriage of severe acute respiratory syndrome coronavirus 2 in nonsymptomatic people and efficacy of mouthrinse in reducing viral load: A randomized controlled trial</text></passage><passage><infon key="fpage">5059</infon><infon key="issue">12</infon><infon key="lpage">5067</infon><infon key="name_0">surname:Schürmann;given-names:M</infon><infon key="name_1">surname:Aljubeh;given-names:M</infon><infon key="name_2">surname:Tiemann;given-names:C</infon><infon key="name_3">surname:Sudhoff;given-names:H</infon><infon key="pub-id_doi">10.1007/s00405-021-06873-8</infon><infon key="pub-id_pmid">34021807</infon><infon key="section_type">REF</infon><infon key="source">Eur Arch Otorhinolaryngol</infon><infon key="type">ref</infon><infon key="volume">278</infon><infon key="year">2021</infon><offset>24512</offset><text>Mouthrinses against SARS-CoV-2: anti-inflammatory effectivity and a clinical pilot study</text></passage><passage><infon key="fpage">e0259943</infon><infon key="issue">11</infon><infon key="name_0">surname:Bansal;given-names:S</infon><infon key="name_1">surname:Jonsson;given-names:CB</infon><infon key="name_2">surname:Taylor;given-names:SL</infon><infon key="name_3">surname:Figueroa;given-names:JM</infon><infon key="name_4">surname:Dugour;given-names:AV</infon><infon key="name_5">surname:Palacios;given-names:C</infon><infon key="name_6">surname:Vega;given-names:JC</infon><infon key="pub-id_doi">10.1371/journal.pone.0259943</infon><infon key="pub-id_pmid">34797868</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2021</infon><offset>24601</offset><text>Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture</text></passage><passage><infon key="fpage">e0237480</infon><infon key="issue">2</infon><infon key="name_0">surname:Morokutti-Kurz;given-names:M</infon><infon key="name_1">surname:Fröba;given-names:M</infon><infon key="name_2">surname:Graf;given-names:P</infon><infon key="name_3">surname:Große;given-names:M</infon><infon key="name_4">surname:Grassauer;given-names:A</infon><infon key="name_5">surname:Auth;given-names:J</infon><infon key="name_6">surname:Schubert;given-names:U</infon><infon key="name_7">surname:Prieschl-Grassauer;given-names:E</infon><infon key="pub-id_doi">10.1371/journal.pone.0237480</infon><infon key="pub-id_pmid">33596218</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2021</infon><offset>24670</offset><text>Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro</text></passage><passage><infon key="fpage">57</infon><infon key="issue">1</infon><infon key="name_0">surname:Koenighofer;given-names:M</infon><infon key="name_1">surname:Lion;given-names:T</infon><infon key="name_2">surname:Bodenteich;given-names:A</infon><infon key="name_3">surname:Prieschl-Grassauer;given-names:E</infon><infon key="name_4">surname:Grassauer;given-names:A</infon><infon key="name_5">surname:Unger;given-names:H</infon><infon key="name_6">surname:Mueller;given-names:CA</infon><infon key="name_7">surname:Fazekas;given-names:T</infon><infon key="pub-id_doi">10.1186/2049-6958-9-57</infon><infon key="pub-id_pmid">25411637</infon><infon key="section_type">REF</infon><infon key="source">Multidiscip Respir Med</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2014</infon><offset>24750</offset><text>Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials</text></passage><passage><infon key="name_0">surname:Reia;given-names:V</infon><infon key="name_1">surname:Bastos;given-names:R</infon><infon key="name_2">surname:Vilhena;given-names:F</infon><infon key="name_3">surname:Marques Honório;given-names:H</infon><infon key="name_4">surname:Alves;given-names:L</infon><infon key="name_5">surname:Frazão;given-names:P</infon><infon key="name_6">surname:Santos;given-names:P</infon><infon key="pub-id_doi">10.21203/rs.3.rs-1065834/v1</infon><infon key="section_type">REF</infon><infon key="source">Res Sq</infon><infon key="type">ref</infon><infon key="year">2021</infon><offset>24875</offset><text>Population-based virucidal phthalocyanine gargle/rinse protocol to reduce the risk of coronavirus disease- 2019 – a community trial [Preprint]</text></passage><passage><infon key="fpage">1494</infon><infon key="issue">10</infon><infon key="lpage">1401</infon><infon key="name_0">surname:Carrouel;given-names:F</infon><infon key="name_1">surname:Valette;given-names:M</infon><infon key="name_10">surname:Bouscambert-Duchamp;given-names:M</infon><infon key="name_11">surname:Bourgeois;given-names:D</infon><infon key="name_2">surname:Gadea;given-names:E</infon><infon key="name_3">surname:Esparcieux;given-names:A</infon><infon key="name_4">surname:Illes;given-names:G</infon><infon key="name_5">surname:Langlois;given-names:ME</infon><infon key="name_6">surname:Perrier;given-names:H</infon><infon key="name_7">surname:Dussart;given-names:C</infon><infon key="name_8">surname:Tramini;given-names:P</infon><infon key="name_9">surname:Ribaud;given-names:M</infon><infon key="pub-id_doi">10.1016/j.cmi.2021.05.028</infon><infon key="pub-id_pmid">34044151</infon><infon key="section_type">REF</infon><infon key="source">Clin Microbiol Infect</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2021</infon><offset>25020</offset><text>Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial</text></passage><passage><infon key="fpage">500</infon><infon key="lpage">503</infon><infon key="name_0">surname:Rudolph;given-names:P</infon><infon key="name_1">surname:Reimer;given-names:K</infon><infon key="name_2">surname:Mlynski;given-names:G</infon><infon key="name_3">surname:Reese;given-names:M</infon><infon key="name_4">surname:Kramer;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">Hyg Med</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2000</infon><offset>25205</offset><text>Nose compatibility of local antiinfectives – an in-vitro model using ciliated epithelium</text></passage><passage><infon key="fpage">86</infon><infon key="lpage">91</infon><infon key="name_0">surname:Kramer;given-names:A</infon><infon key="name_1">surname:Below;given-names:H</infon><infon key="name_2">surname:Behrens-Baumann;given-names:W</infon><infon key="name_3">surname:Müller;given-names:G</infon><infon key="name_4">surname:Rudolph;given-names:P</infon><infon key="name_5">surname:Reimer;given-names:K</infon><infon key="pub-id_doi">10.1159/000057732</infon><infon key="section_type">REF</infon><infon key="source">Dermatology</infon><infon key="type">ref</infon><infon key="volume">204 Suppl 1</infon><infon key="year">2002</infon><offset>25296</offset><text>New aspects of the tolerance of the antiseptic povidone-iodine in different ex vivo models</text></passage><passage><infon key="fpage">789</infon><infon key="issue">6</infon><infon key="lpage">793</infon><infon key="name_0">surname:Hansmann;given-names:F</infon><infon key="name_1">surname:Below;given-names:H</infon><infon key="name_2">surname:Kramer;given-names:A</infon><infon key="name_3">surname:Müller;given-names:G</infon><infon key="name_4">surname:Geerling;given-names:G</infon><infon key="pub-id_doi">10.1007/s00417-006-0320-8</infon><infon key="pub-id_pmid">17186264</infon><infon key="section_type">REF</infon><infon key="source">Graefes Arch Clin Exp Ophthalmol</infon><infon key="type">ref</infon><infon key="volume">245</infon><infon key="year">2007</infon><offset>25387</offset><text>Prospective study to determine the penetration of iodide into the anterior chamber following preoperative application of topical 1.25% povidone-iodine</text></passage><passage><infon key="fpage">401</infon><infon key="issue">3</infon><infon key="lpage">403</infon><infon key="name_0">surname:Richter;given-names:R</infon><infon key="name_1">surname:Below;given-names:H</infon><infon key="name_2">surname:Kadow;given-names:I</infon><infon key="name_3">surname:Kramer;given-names:A</infon><infon key="name_4">surname:Müller;given-names:C</infon><infon key="name_5">surname:Fusch;given-names:C</infon><infon key="pub-id_doi">10.1016/j.jpeds.2005.10.024</infon><infon key="pub-id_pmid">16615978</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr</infon><infon key="type">ref</infon><infon key="volume">148</infon><infon key="year">2006</infon><offset>25538</offset><text>Effect of topical 1.25% povidone-iodine eyedrops used for prophylaxis of ophthalmia neonatorum on renal iodine excretion and thyroid-stimulating hormone level</text></passage><passage><infon key="fpage">279</infon><infon key="issue">4</infon><infon key="lpage">282</infon><infon key="name_0">surname:Razavi;given-names:B</infon><infon key="name_1">surname:Zollinger;given-names:R</infon><infon key="name_2">surname:Kramer;given-names:A</infon><infon key="name_3">surname:Fricke;given-names:C</infon><infon key="name_4">surname:Völzke;given-names:H</infon><infon key="name_5">surname:Jäger;given-names:B</infon><infon key="name_6">surname:Spielhagen;given-names:C</infon><infon key="name_7">surname:Behrens-Baumann;given-names:W</infon><infon key="name_8">surname:Below;given-names:H</infon><infon key="pub-id_doi">10.3109/15569527.2013.776574</infon><infon key="pub-id_pmid">23528074</infon><infon key="section_type">REF</infon><infon key="source">Cutan Ocul Toxicol</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2013</infon><offset>25697</offset><text>Systemic iodine absorption associated with the use of preoperative ophthalmic antiseptics containing iodine</text></passage><passage><infon key="fpage">661</infon><infon key="issue">8664</infon><infon key="lpage">664</infon><infon key="name_0">surname:Smerdely;given-names:P</infon><infon key="name_1">surname:Lim;given-names:A</infon><infon key="name_2">surname:Boyages;given-names:SC</infon><infon key="name_3">surname:Waite;given-names:K</infon><infon key="name_4">surname:Wu;given-names:D</infon><infon key="name_5">surname:Roberts;given-names:V</infon><infon key="name_6">surname:Leslie;given-names:G</infon><infon key="name_7">surname:Arnold;given-names:J</infon><infon key="name_8">surname:John;given-names:E</infon><infon key="name_9">surname:Eastman;given-names:CJ</infon><infon key="pub-id_doi">10.1016/s0140-6736(89)90903-3</infon><infon key="pub-id_pmid">2570908</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1989</infon><offset>25805</offset><text>Topical iodine-containing antiseptics and neonatal hypothyroidism in very-low-birthweight infants</text></passage><passage><infon key="fpage">241</infon><infon key="issue">3</infon><infon key="lpage">247</infon><infon key="name_0">surname:Selvaggi;given-names:G</infon><infon key="name_1">surname:Monstrey;given-names:S</infon><infon key="name_2">surname:Van Landuyt;given-names:K</infon><infon key="name_3">surname:Hamdi;given-names:M</infon><infon key="name_4">surname:Blondeel;given-names:P</infon><infon key="pub-id_doi">10.1080/00015458.2003.11679417</infon><infon key="pub-id_pmid">12914356</infon><infon key="section_type">REF</infon><infon key="source">Acta Chir Belg</infon><infon key="type">ref</infon><infon key="volume">103</infon><infon key="year">2003</infon><offset>25903</offset><text>The role of iodine in antisepsis and wound management: a reappraisal</text></passage><passage><infon key="fpage">414</infon><infon key="issue">5</infon><infon key="lpage">419</infon><infon key="name_0">surname:Leung;given-names:AM</infon><infon key="name_1">surname:Braverman;given-names:LE</infon><infon key="pub-id_doi">10.1097/MED.0b013e3283565bb2</infon><infon key="pub-id_pmid">22820214</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Endocrinol Diabetes Obes</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2012</infon><offset>25972</offset><text>Iodine-induced thyroid dysfunction</text></passage><passage><infon key="fpage">465</infon><infon key="issue">9</infon><infon key="lpage">466</infon><infon key="name_0">surname:Burchés-Feliciano;given-names:MJ</infon><infon key="name_1">surname:Argente-Pla;given-names:M</infon><infon key="name_2">surname:García-Malpartida;given-names:K</infon><infon key="name_3">surname:Rubio-Almanza;given-names:M</infon><infon key="name_4">surname:Merino-Torres;given-names:JF</infon><infon key="pub-id_doi">10.1016/j.endoen.2015.11.003</infon><infon key="pub-id_pmid">26277578</infon><infon key="section_type">REF</infon><infon key="source">Endocrinol Nutr</infon><infon key="type">ref</infon><infon key="volume">62</infon><infon key="year">2015</infon><offset>26007</offset><text>Hyperthyroidism induced by topical iodine</text></passage><passage><infon key="fpage">586</infon><infon key="issue">9</infon><infon key="lpage">593</infon><infon key="name_0">surname:Frank;given-names:S</infon><infon key="name_1">surname:Capriotti;given-names:J</infon><infon key="name_2">surname:Brown;given-names:SM</infon><infon key="name_3">surname:Tessema;given-names:B</infon><infon key="pub-id_doi">10.1177/0145561320932318</infon><infon key="pub-id_pmid">32520599</infon><infon key="section_type">REF</infon><infon key="source">Ear Nose Throat J</infon><infon key="type">ref</infon><infon key="volume">99</infon><infon key="year">2020</infon><offset>26049</offset><text>Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era</text></passage><passage><infon key="fpage">141</infon><infon key="issue">1</infon><infon key="lpage">147</infon><infon key="name_0">surname:Jackson;given-names:WM</infon><infon key="name_1">surname:Price;given-names:JC</infon><infon key="name_2">surname:Eisler;given-names:L</infon><infon key="name_3">surname:Sun;given-names:LS</infon><infon key="name_4">surname:Lee;given-names:JJ</infon><infon key="pub-id_doi">10.1097/ANA.0000000000000803</infon><infon key="pub-id_pmid">34870638</infon><infon key="section_type">REF</infon><infon key="source">J Neurosurg Anesthesiol</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2022</infon><offset>26140</offset><text>COVID-19 in Pediatric Patients: A Systematic Review</text></passage><passage><infon key="comment">Available from: https://apps.who.int/iris/handle/10665/333625</infon><infon key="section_type">REF</infon><infon key="source">Considerations for the provision of essential oral health services in the context of COVID-19: interim guidance, 3 August 2020</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>26192</offset></passage><passage><infon key="fpage">e210018</infon><infon key="name_0">surname:Justo;given-names:AFO</infon><infon key="name_1">surname:Bueno;given-names:MS</infon><infon key="name_2">surname:Barbosa;given-names:GR</infon><infon key="name_3">surname:Perosa;given-names:AH</infon><infon key="name_4">surname:Carvalho;given-names:JM</infon><infon key="name_5">surname:Bellei;given-names:N</infon><infon key="pub-id_doi">10.1590/0074-02760210018</infon><infon key="pub-id_pmid">33886872</infon><infon key="section_type">REF</infon><infon key="source">Mem Inst Oswaldo Cruz</infon><infon key="type">ref</infon><infon key="volume">116</infon><infon key="year">2021</infon><offset>26193</offset><text>Comparison of viral load between saliva and nasopharyngeal swabs for SARS-CoV2: the role of days of symptoms onset on diagnosis</text></passage><passage><infon key="comment">Available from: https://www.awmf.org/leitlinien/detail/ll/083-046.html</infon><infon key="section_type">REF</infon><infon key="source">S1-Leitlinie Umgang mit zahnmedizinischen Patienten bei Belastung mit Aerosol-übertragbaren Erregern. Registernummer 083-046</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>26321</offset></passage><passage><infon key="comment">Available from: https://www.awmf.org/leitlinien/detail/ll/080-008.html</infon><infon key="section_type">REF</infon><infon key="source">S2k-Leitlinie SARS-CoV-2, COVID-19 und (Früh-) Rehabilitation. Registernummer 080-008</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>26322</offset></passage><passage><infon key="section_type">REF</infon><infon key="source">Deutscher Arzneimittel-Codex® / Neues Rezeptur-Formularium® (DAC/NRF). Ergänzungsbuch zum Arzneibuch</infon><infon key="type">ref</infon><infon key="year">2021</infon><offset>26323</offset></passage></document></collection>
